Floatz logo

Devimistat

Granulocytic Sarcoma

Wake Forest University Health SciencesSmall moleculePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Granulocytic Sarcoma cohort.

Asset / SponsorPhaseRating
Metformin
Wake Forest University Health Sciences
Phase 2CCC
Mitoxantrone
Wake Forest University Health Sciences
Phase 1CC
Cytosin-Arabinosid
Wake Forest University Health Sciences
Phase 1CC

Same molecule, other indications

Devimistat is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →